SURVEY OF INSTITUTIONAL HANDLING OF REGENERATIVE MEDICAL PRODUCTS CONDUCTED BY THE JAPAN SOCIETY OF TRANSFUSION MEDICINE AND CELL THERAPY IN 2022

DOI Web Site 7 References
  • Kobayashi Hirohito
    Division of Transfusion and Cell Therapy, Tokyo Women's Medical University, Adachi Medical Center Department of Transfusion and Cell Processing, Tokyo Women's Medical University Hospital
  • Yakushijin Kimikazu
    Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine
  • Anan Masahiro
    Department of Transfusion Medicine, Saitama Medical Center, Saitama Medical University
  • Ikeda Kazuhiko
    Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine
  • Okuyama Yoshiki
    Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
  • Fujiwara Shin-ichiro
    Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital
  • Kanno Hitoshi
    Department of Transfusion and Cell Processing, Tokyo Women's Medical University Hospital
  • Tanosaki Ryuji
    Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine
  • Nakayama Takayuki
    Clinical Laboratory, Aichi Medical University
  • Nagamura-Inoue Tokiko
    Department of Cell Processing and Transfusion, Research Hospital, The Institute of Medical Science, The University of Tokyo

Bibliographic Information

Other Title
  • 日本輸血・細胞治療学会による「院内細胞治療製品取扱実態調査」における再生医療等製品2022年の現状

Search this article

Description

<p>In 2022, we conducted a survey to assess how institutions were handling regenerative medical products. The survey was distributed to 203 facilities, including university hospitals, national and public hospitals, Japan Marrow Donor Program-certified hospitals, children's hospitals, and perinatal medical centers. A total of 140 facilities responded. The current status of in-hospital adoption of regenerative medical products is as follows: among 11 types of human cell/tissue products, Temcell® HS had the high usage rate of 80.7%, while Kymriah® (Tisagenlecleucel) had a usage rate of 28.6%. Of the three types of gene therapy product, Zolgensma® (Onasemnogene abeparvovec-xioi) had the highest usage rate at 18.6%. Regarding transfusion departments, while these were involved in the apheresis and management of regenerative medical products, they had was no involvement with Nepic® or Ocural®. It should be noted that these products are specified as designated-regenerative medical products, and the storage of administration records within the institution is therefore mandated, similarly as for blood products. Some of these products involve the participation of specialized departments, but the majority were under management of the respective medical department and pharmacy division. This survey highlighted challenges in the management and handling of regenerative medical products within the hospital from the perspective of the transfusion department.</p>

Journal

References(7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top